TCT 2018 | SORT OUT IX: Polymer-Free DES with Ultra-Thin Struts vs. Bioresorbable Polymer- Based DES

Polymer persistence in 1st and 2nd generation DES meant to allow drug release has been associated with a chronic inflammatory response that might be associated to restenosis, neo atherosclerosis and stent thrombosis.

TCT 2018 | SORT OUT IX: Stent libre de polímero y struts ultrafinos vs polímero bio absorbibleThis is the rationale behind the development of polymer free and bioresorbable polymer-based DES. They have both been compared against permanent polymer DES, but never against each other.

 

This single blind randomized study of all-comers had a non-inferiority design and compared the polymer free Biolimus A9 (BioFreedom) against the bioresorbable sirolimus DES with ultra-thin struts (Orsiro).

 

Dual antiaggregation was indicated for 6 months (AAS plus clopidogrel) in stable patients and for one year (AAS plus ticagrelor or prasugrel) for patients undergoing acute coronary syndrome.


Read also: TCT 2018 | IMPERIAL: First Study Comparing Drug-Eluting Stents in Patients with Femoropopliteal Disease.


It included 3151 patients (1572 for BioFreedom vs 1579 for Orsiro).

 

Primary end point was target vessel failure (classic composite) which resulted 5.3% for BioFreedom vs 4% for Orsiro, with the latter reaching non-inferiority.

 

Definite thrombosis resulted identical, with 0.7% for each device, and there was an advantage for Orsiro in terms of revascularization, with 1.3% vs 3.5% for BioFreedom.


Read also: TCT 2018 | LEADERS FREE II: Polymer-Free DES in Patients at High Risk for Bleeding with 1 Month of Antiplatelet Therapy.


The study reached non-inferiority in an unselected population (all comers) showing the safety of both devices, with an advantage for Orsiro only in terms of revascularization.

 

Original title: SORT OUT IX: A Randomized Trial Comparing a Polymer-Free Coronary Drug-Eluting Stent with an Ultra-Thin Strut Bioresorbable Polymer- Based Drug-Eluting Stent in an All-Comers Patient Population.

Presenter: Lisette Okkels Jensen.

 

SORT-OUT-IX


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....